Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Pancreatic Neoplasms 16Carcinoma, Non-Small-Cell Lung 16Breast Neoplasms 15Triple Negative Breast Neoplasms 12Lung Neoplasms 12Neoplasm Metastasis 11Ovarian Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Fallopian Tube Neoplasms 7Endometrial Neoplasms 7Esophageal Neoplasms 5Oropharyngeal Neoplasms 4Neoplasms 4Melanoma 4Colorectal Neoplasms 4Adenocarcinoma Of Esophagus 4Mouth Neoplasms 3Laryngeal Neoplasms 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Carcinoma 3Stomach Neoplasms 2Inflammatory Breast Neoplasms 2Hypopharyngeal Neoplasms 2Head and Neck Neoplasms 2Gallbladder Neoplasms 2Esophageal Squamous Cell Carcinoma 2Brenner Tumor 2Anatomic Stage II Breast Cancer AJCC v8 2Anatomic Stage I Breast Cancer AJCC v8 2

Interventions

trastuzumab biosimilar HLX02 1exemestane 1X-Rays 1Trastuzumab 1Taxes 1TVB-2640 1Specimen Handling 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1Magnetic Resonance Spectroscopy 1Letrozole 1Fulvestrant 1Disulfides 1CT-P6 1Biopsy 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Breast Carcinoma × Taxes × 90 days × Clear all
NCT03179904 2026-05-05

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Mayo Clinic

Phase 2 Active not recruiting
17 enrolled 10 charts
Breast

Advanced Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡